Skip to Main Content

Paper Details

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
Haematologica
22
2021
Author NameAffiliation
Suzanne Kamel-ReidPrincess Margaret Cancer Centre, University Health Network
Aaron D SchimmerPrincess Margaret Cancer Centre, University Health Network
  • 1 - 2

Datasets

Release 1.2